PRKG2

PRKG2 encodes cGMP-dependent protein kinase II (cGKII), a membrane-associated serine/threonine kinase that transduces nitric oxide/cGMP signaling into phosphorylation of diverse substrates across multiple tissues. In neurons, cGKII directly binds and phosphorylates GluA1 at Ser845, promoting AMPAR surface insertion to regulate synaptic plasticity and seizure susceptibility, and controls presynaptic vesicle endocytosis at cerebellar synapses (PMID:18031684, PMID:29587280, PMID:29084181). In chondrocytes, cGKII phosphorylates c-Raf1 at Ser43 to activate ERK1/2 downstream of FGF signaling and regulates SOX9-dependent collagen gene expression required for the proliferative-to-hypertrophic transition; biallelic loss-of-function mutations cause acromesomelic dysplasia (dwarfism) in humans and cattle (PMID:33106379, PMID:19887637, PMID:41574272). cGKII additionally phosphorylates NHE3 at three obligate serine residues to inhibit intestinal sodium/hydrogen exchange, phosphorylates MYRF at Ser259 to suppress myelin gene transcription, and signals through AKT/CREB to regulate developmental cell survival in the retina (PMID:25480791, PMID:32270922, PMID:24531539).

1. 2007 High

   Establishing that cGKII is not merely a cytoplasmic signaling kinase but directly binds its substrate GluA1 and phosphorylates Ser845 to drive AMPAR surface expression and LTP answered how cGMP signaling regulates excitatory synaptic strength.

   Evidence Co-IP from brain, pulldown assays, surface biotinylation, hippocampal slice LTP recordings

   PMID:18031684

   Open questions at the time

   • Identity of additional neuronal cGKII substrates beyond GluA1
   • Whether cGKII-GluA1 interaction is regulated by other post-translational modifications
   • Structural basis of the cGKII–GluA1 C-terminal binding interface
2. 2008 Medium

   Discovery of a PRKG2-PDGFRB fusion in myeloproliferative disease revealed that the PRKG2 locus can participate in oncogenic rearrangements, though the fusion's transforming activity derives from constitutive PDGFRB kinase activation rather than cGKII function.

   Evidence FISH, fusion transcript cloning, transforming assay, imatinib sensitivity in a single patient case

   PMID:18166785

   Open questions at the time

   • Single case report; frequency of this translocation is unknown
   • Whether PRKG2 regulatory elements contribute to fusion expression levels
3. 2009 Medium

   Identification of a truncating PRKG2 mutation (R678X) in dwarfed cattle that failed to suppress COL2 expression established that the kinase domain is essential for regulating chondrocyte differentiation programs.

   Evidence Genetic mapping in Angus cattle pedigrees, overexpression of WT vs. R678X PRKG2, RT-PCR for COL2/COL10

   PMID:19887637

   Open questions at the time

   • Direct phosphorylation substrate linking cGKII kinase activity to SOX9/collagen regulation was not identified
   • No rescue experiment restoring WT PRKG2 in mutant chondrocytes
4. 2010 Low

   Promoter analysis identified a functional Nkx-binding site required for PRKG2 transcription in chondrocytes, providing a first clue to how PRKG2 itself is transcriptionally induced before hypertrophic differentiation.

   Evidence Promoter-luciferase deletion/mutagenesis in chondrogenic ATDC5 cells, RT-PCR time course

   PMID:20057151

   Open questions at the time

   • No direct Nkx protein binding confirmed by EMSA or ChIP
   • Identity of the specific Nkx family member driving PRKG2 transcription remains unresolved
   • Relevance to in vivo chondrocyte differentiation not tested
5. 2014 High

   Phosphoproteomic identification of three obligate NHE3 phosphosites and demonstration that all three are simultaneously required for cGKII-mediated inhibition of Na+/H+ exchange resolved the molecular mechanism by which cGMP controls intestinal sodium absorption.

   Evidence iTRAQ/LC-MS/MS with TiO2 enrichment, site-directed mutagenesis, surface biotinylation, fluorometric NHE3 activity assay in cell lines and mouse ileum

   PMID:25480791

   Open questions at the time

   • Structural basis for requirement of all three sites simultaneously
   • Whether cGKII phosphorylates NHE3 directly or through an intermediate kinase in vivo
6. 2014 Medium

   Showing that cGKII mediates opposing developmental outcomes—promoting apoptosis at E6 but survival at E8—through stage-dependent AKT and CREB phosphorylation revealed that cGKII's downstream signaling output is context-dependent in retinal neurons.

   Evidence shRNA knockdown in chick retina, pharmacological sGC/cGK inhibition, nuclear phospho-CREB and phospho-AKT immunostaining, caspase activation

   PMID:24531539

   Open questions at the time

   • Direct substrate linking cGKII to AKT phosphorylation not identified
   • Mechanism of developmental switch in cGKII signaling output unknown
7. 2017 Medium

   Demonstration that cGKII knockout slows synaptic vesicle endocytosis and alters synapse ultrastructure in cerebellar granule cells established a presynaptic role for cGKII distinct from its postsynaptic GluA1 phosphorylation function.

   Evidence cGKII knockout mice, live vesicle recycling imaging, electron microscopy of cerebellar synapses

   PMID:29084181

   Open questions at the time

   • Presynaptic substrates of cGKII mediating endocytosis not identified
   • Whether this presynaptic role operates in brain regions beyond cerebellum
8. 2018 Medium

   Replication of the cGKII–GluA1 Ser845 phosphorylation axis in an epilepsy model, showing that cGKII activation increases seizure activity via enhanced AMPAR surface expression, translated the earlier biochemical finding into a disease-relevant context.

   Evidence Pharmacological cGKII activation/inhibition in pilocarpine rat model, electrophysiology, phospho-Ser845-GluA1 immunoblotting

   PMID:29587280

   Open questions at the time

   • Genetic validation (cGKII knockout in epilepsy model) not performed
   • Whether cGKII contributes to epileptogenesis or only modulates established seizures
9. 2020 Medium

   Identification of MYRF Ser259 as a cGKII phosphosite that promotes MYRF–mutant huntingtin binding and suppresses myelin gene expression connected cGKII to oligodendrocyte pathology in Huntington's disease and revealed a non-neuronal CNS substrate.

   Evidence PRKG2 knockdown in HD mouse oligodendrocytes, phospho-specific immunoblotting, co-IP, myelin gene expression analysis

   PMID:32270922

   Open questions at the time

   • Whether MYRF phosphorylation by cGKII occurs in wild-type myelination or only in HD context
   • Structural basis of phospho-MYRF–huntingtin interaction unknown
10. 2020 Medium

    Biallelic PRKG2 loss-of-function variants in human acromesomelic dysplasia patients were shown to abolish c-Raf1 Ser43 phosphorylation and ERK1/2 activation, directly linking cGKII kinase activity to FGF/MAPK signaling in chondrocyte hypertrophy and establishing the human disease mechanism.

    Evidence Exome sequencing of affected families, functional characterization of mutant proteins, phospho-Raf1/phospho-ERK immunoblotting, COL10A1/COL2A1 expression

    PMID:33106379

    Open questions at the time

    • Whether c-Raf1 is a direct or indirect cGKII substrate in chondrocytes not formally resolved
    • In vivo rescue of skeletal phenotype by WT PRKG2 not demonstrated
11. 2020 Medium

    Confirmation in cGKII knockout mice that cGKII is required for cycloheximide-induced AKT phosphorylation in retina placed cGKII as a necessary node between cGMP production and AKT/ERK activation under translational stress.

    Evidence cGKII knockout mice, shRNA knockdown, NOS/sGC pharmacological inhibition, phospho-AKT and phospho-ERK immunoblotting

    PMID:32360667

    Open questions at the time

    • Direct cGKII substrate connecting to AKT phosphorylation still not identified
    • Relevance beyond retinal neurons not explored
12. 2022 Medium

    Prkg2 knockout AT2 cells forming more organoids but differentiating preferentially toward AT1 fate revealed a role for cGKII in suppressing alveolar progenitor cell lineage transition, broadening its known biology beyond neurons and cartilage.

    Evidence Prkg2 knockout mice, 3D AT2 organoid co-culture, EdU proliferation, AT1/AT2 marker immunostaining, PKA inhibitor treatment

    PMID:35313961

    Open questions at the time

    • Substrates mediating cGKII's effect on AT2-to-AT1 differentiation unknown
    • Relationship between cGKII and PKA signaling in this context mechanistically undefined

• Key unresolved questions include the structural basis of cGKII substrate selectivity across its diverse tissue-specific targets, the direct substrates linking cGKII to AKT activation, and whether cGKII's role in alveolar and osteoblast differentiation shares a common downstream pathway with its chondrocyte function.
• No crystal structure of full-length cGKII or cGKII–substrate complex
• No unbiased phosphoproteomics across multiple cGKII-expressing tissues
• Mechanism of cGKII turnover by SMURF1-mediated ubiquitination awaits independent confirmation